Immunomodulatory therapies for autoimmune diseases
Citation:
SULAIMANI, JAMAL, Immunomodulatory therapies for autoimmune diseases, Trinity College Dublin.School of Biochemistry & Immunology, 2019Download Item:
Abstract:
Multiple sclerosis (MS) and psoriasis are both T cell mediated autoimmune diseases that are
triggered in genetically susceptible individuals in response to environmental factors. Th17
cells are strongly implicated in the pathogenesis of both MS and psoriasis, whereas Treg
cells suppress effector T cell responses and prevent autoimmunity, however, their function
has been shown to be impaired in both diseases. Therefore, targeting the Treg:Th17 axis is
of great therapeutic interest in such autoimmune diseases. Therapies for both MS and
psoriasis include a range of biologics or small molecules, some of which have very specific
mechanisms of action whereas others have broader and less well understood mechanisms of
action. Unfortunately most of these therapies can be associated with undesirable side effects
and not all patients respond to treatment. Therefore, there is a need for safer therapies and a
better understanding of the mechanisms of action of existing therapies.
It has been established that vitamin D can exert anti-inflammatory effects in vitro and in vivo
in the animal model for MS, prompting the idea of testing oral vitamin D3 supplementation
as a therapy for MS. Vitamin D3 is an attractive therapy as it is safe and taken orally, however
its efficacy in MS has not yet been established. A double-blind placebo-controlled
randomised trial was conducted to examine the immunomodulatory effects of vitamin D3 in
healthy controls (HC) (n=38) and clinically isolated syndrome (CIS) patients (n=29). CIS
patients, who are those who have experienced only a single clinical neurological episode,
were selected since they do not qualify for standard therapies, allowing for the effects of
vitamin D3 supplementation to be assessed in isolation. However, although vitamin D3
supplementation increased serum 25(OH)D from baseline in both HC and CIS patients, no
clinical or immunomodulatory effects on T cell subsets were observed and the trial did not
meet its endpoints.
Dimethyl fumarate (DMF) is the active ingredient in Fumaderm™, an oral drug which is
used for the treatment of psoriasis, and DMF is now also used to treat MS. However, there
is a need to better understand the mechanism of action of DMF both in vitro, and in vivo in
psoriasis patients since it is poorly understood. Thus, the immunomodulatory effects of both
vitamin D3 and DMF were examined in this study. In vitro studies using DMF revealed that
the oxidative stress induced by DMF provided a relative advantage to Treg cells via their
increased ability to resist oxidative stress. Furthermore, an increased frequency of Treg cells
was also observed in psoriasis patients who had been treated with Fumaderm™, and this was
associated with a significant decrease in memory CD4+ T cells and more specifically Th17
lineage cells.
In summary, this study has provided useful information on the safety and dosage of vitamin
D3 supplementation, but could not demonstrate clinical efficacy or immunomodulatory
effects on T cell subsets. However this study has provided novel insights into the mechanism
of action of DMF in vitro and in vivo, demonstrating that DMF modulated the Treg:Th17
axis in favour of Treg cells both in vitro and in vivo in psoriasis patients treated with
Fumaderm™.
Sponsor
Grant Number
Other
Saudi Cultural Bureau
Author's Homepage:
https://tcdlocalportal.tcd.ie/pls/EnterApex/f?p=800:71:0::::P71_USERNAME:SULAIMAJDescription:
APPROVED
Author: SULAIMANI, JAMAL
Advisor:
Fletcher, JeanPublisher:
Trinity College Dublin. School of Biochemistry & Immunology. Discipline of BiochemistryType of material:
ThesisAvailability:
Full text availableMetadata
Show full item recordLicences: